Brief: Uniqure Provides Regulatory Update On Amt-130 For Huntington’S Disease
02/03/2026 14:14
March 2 (Reuters) - Uniqure NV UQ1.F: UNIQURE PROVIDES REGULATORY UPDATE ON AMT-130 FOR HUNTINGTON’S DISEASE UNIQURE NV - FDA STATES PHASE I/II DATA INSUFFICIENT FOR AMT-130 MARKETING APPLICATION UNIQURE NV - FDA RECOMMENDS RANDOMIZED DOUBLE-BLIND STUDY FOR AMT-130 UNIQURE NV - PLANS TYPE B MEETING WITH FDA IN Q2 2026 Source text: ID:nGNX7QF3wD Further company coverage: UQ1.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal